Attralus logo
  • Home
  • Company
    • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Science
    • Approach
    • Pan-Amyloid Removal (PAR)
    • Pan-Amyloid Diagnostic
    • Neurodegenerative Diseases
  • Pipeline
  • News
    • Press Releases
    • Posters & Publications
    • In the News
  • Amyloidosis
  • Careers
  • Contact
Attralus logo
  • Home
  • Company
    • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Science
    • Approach
    • Pan-Amyloid Removal (PAR)
    • Pan-Amyloid Diagnostic
    • Neurodegenerative Diseases
  • Pipeline
  • News
    • Press Releases
    • Posters & Publications
    • In the News
  • Amyloidosis
  • Careers
  • Contact
Attralus Receives Breakthrough Therapy Designation for its Pan-Amyloid Diagnostic PET Imaging Candidate 124I-evuzamitide (AT-01) for Cardiac Amyloidosis

Attralus Receives Breakthrough Therapy Designation for its Pan-Amyloid Diagnostic PET Imaging Candidate 124I-evuzamitide (AT-01) for Cardiac Amyloidosis

Aug 5, 2024 Press Releases

PDF Version 124I-evuzamitide (AT-01) is one of the first investigational diagnostic imaging agents to receive Breakthrough Therapy Designation (BTD) from the US Food and Drug Administration (FDA), and the only diagnostic imaging agent that has received BTD for cardiac...

Recent Posts

  • Attralus Presents New Data on Its Pan-Amyloid Diagnostic Candidates at the 2025 American College of Cardiology (ACC) Annual Scientific Session
  • Detection Of Cardiac Amyloidosis, and More, Using SPECT/CT Imaging of Technetium-99m-Labeled Peptide P5+14 (At-05)
  • Reliability Of 124I-evuzamitide Imaging and Quantitative Agreement in Patients with AL and ATTR Systemic Amyloidosis
  • Automated Quantification of AL and ATTR Systemic Amyloid Burden Using 124I-evuzamitide, a Novel Pan-Amyloid Radiotracer
  • Diagnostic Performance of Cardiac and Whole-Body 124I-Evuzamitide (AT-01) PET/MRI in Systemic Amyloidosis

Recent Comments

No comments to show.
COMPANY
About
Management Team
Board of Directors
Scientific Advisory Board
Investors

SCIENCE
Approach
Pan-Amyloid Removal (PAR)
Pan-Amyloid Diagnostic
Neurodegenerative Diseases

PIPELINE

 

NEWS
Press Releases
Posters & Publications
In the News

HOME
AMYLOIDOSIS
CAREERS
CONTACT
  • Privacy Policy
  • Terms of Service
  • Follow
  • Follow
Attralus logo

Attralus, Inc.
365 Fifth Ave South, Ste 208
Naples, FL 34102

©2024 Attralus, Inc.  All Rights Reserved.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. Read More
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT
Powered by CookieYes Logo